BIOLOGIC/DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARD)
Abrilada is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with moderately to severely active rheumatoid arthritis. Abrilada is also referred to by its drug name, adalimumab-afzb.
Abrilada is a biologic drug. Abrilada is also considered a disease-modifying antirheumatic drug (DMARD). It is believed to work by suppressing the inflammatory immune response brought about by the cell-signaling protein TNF, thereby reducing symptoms of rheumatoid arthritis and other immune-system diseases. Abrilada is biologically similar to the FDA-approved drug Humira (adalimumab).
How do I take it?
Prescribing information states that Abrilada is taken as a subcutaneous injection every other week.
Abrilada is available as a prefilled single-dose glass syringe.
The FDA-approved label for Abrilada lists common side effects including infections, injection site reactions, headache, and rash.
Rare but serious side effects listed for Abrilada include severe infections, lymphoma and other cancers, severe allergic reactions, nerve disorders such as multiple sclerosis and Guillain-Barré syndrome, hepatitis B virus reactivation, low blood cell counts, heart failure, and lupus-like syndrome.
For more details about this treatment, visit:
Abrilada — RxList
Adalimumab (Subcutaneous Route) — Mayo Clinic